DERM Stock Summary and Trading Ideas (Journey Medical | NASDAQ:DERM)

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Journey Medical trades on the NASDAQ stock market under the symbol DERM.

As of April 18, 2024, DERM stock price declined to $3.58 with 189,096 million shares trading.

DERM has a beta of -0.26, meaning it tends to be less sensitive to market movements. DERM has a correlation of 0.00 to the broad based SPY ETF.

DERM has a market cap of $66.26 million. This is considered a Micro Cap stock.

Last quarter Journey Medical reported $15 million in Revenue and $.03 earnings per share. This beat revenue expectation by $197,000 and exceeded earnings estimates by $.11.

The top ETF exchange traded funds that DERM belongs to (by Net Assets): VTI, VXF, IWC, SQLV.

DERM has outperformed the market in the last year with a price return of +132.5% while the SPY ETF gained +22.3%. However, in the short term, DERM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -29.9% vs +6.1% return in SPY. But in the last 2 weeks, DERM shares have fared better than the market returning +4.7% compared to SPY -3.8%.

DERM support price is $3.50 and resistance is $4.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DERM stock will trade within this expected range on the day.